In vitro effect of aspartame in angiogenesis induction

Toxicol In Vitro. 2011 Feb;25(1):286-93. doi: 10.1016/j.tiv.2010.09.002. Epub 2010 Sep 17.

Abstract

Aspartame (APM) is the most widely used artificial sweetener and is added to a wide variety of foods, beverages, drugs, and hygiene products. In vitro and in vivo tests have reported contradictory data about APM genotoxicity. We evaluated the angiogenic effect of APM in an in vitro model using blood vessel development assay (Angio-Kit), cultured endothelial cells and fibroblasts. The release of IL-6, VEGF-A, and their soluble receptors sIL-R6 and sVEGFR-2 were determined over time in the conditioned medium of the Angio-Kit system, endothelial cells and cell lines with fibroblast properties after APM treatment. Reactive oxygen species (ROS) formation, cell viability, and stimulation of the extracellular signal-regulated kinases (erk1/2) and protein p38 were also evaluated. Exposure to APM induced blood vessel formation. ROS production was observed in endothelial cells after APM treatment, which was associated with a slight cell cytotoxicity. Neither intracellular ROS formation nor cell death was observed in fibroblasts. APM increases the levels of inflammatory mediator IL-6, VEGF and their soluble receptors released from endothelial cells into the medium. APM treatment induces VEGF-pathway activation by erk1/2 and p38 phosphorylation. APM at low doses is an angiogenic agent that induces regenerative cytokine production leading to the activation of MAPKs and resulting in the formation of new blood vessels.

MeSH terms

  • Angiogenesis Inducing Agents / pharmacology*
  • Aspartame / pharmacology*
  • Cell Line
  • Cell Survival / drug effects
  • Cells, Cultured
  • Coculture Techniques
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • Humans
  • Interleukin-6 / metabolism
  • MAP Kinase Signaling System / drug effects
  • Neovascularization, Physiologic / drug effects*
  • Osmolar Concentration
  • Reactive Oxygen Species
  • Receptors, Interleukin-6 / metabolism
  • Solubility
  • Sweetening Agents / pharmacology*
  • Time Factors
  • Vascular Endothelial Growth Factor A / metabolism
  • Vascular Endothelial Growth Factor Receptor-2 / metabolism

Substances

  • Angiogenesis Inducing Agents
  • IL6 protein, human
  • IL6R protein, human
  • Interleukin-6
  • Reactive Oxygen Species
  • Receptors, Interleukin-6
  • Sweetening Agents
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-2
  • Aspartame